Synopsis of recent research by authors named "Silvia Foti"
- Silvia Foti's recent research primarily focuses on the treatment and outcomes of hepatocellular carcinoma (HCC), emphasizing the effectiveness of various therapeutic approaches including atezolizumab combined with bevacizumab and lenvatinib as second-line treatments.
- The studies highlight the importance of disease etiology, body mass index, and adverse events in influencing the prognosis and therapeutic responses of HCC patients, suggesting these factors could be predictive markers for treatment outcomes.
- Foti's research includes a retrospective analysis of large, multicenter datasets, providing insights into the real-world efficacy of these treatments and the potential of biologics and targeted therapies in managing advanced liver cancers.
